Industry-Supported Symposium

ITS12: Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition

Industry Presenter(s)

• 

  Philip Mease, MD

  Rheumatologist, Director of Rheumatology Research, Clinical Professor Director of Rheumatology Research Swedish Medical Center/Providence-St Joseph Health
  Swedish Medical Center/Providence St. Joseph Health
  Seattle, Washington, United States

  Disclosure(s): AbbVie/Abbott: Consultant (Terminated), Grant/Research Support (Terminated), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Acelyrin: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Century: Consultant (Ongoing); Cullinan Biotech: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Genascence: Data Safety Board (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Moonlake: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Takeda: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  Atul Deodhar, MD

  Professor of Medicine, Division of Arthritis and Rheumatic Diseases, School of Medicine
  Oregon Health & Science University
  Portland, Oregon, United States

  Disclosure information not submitted.
• LE

  Lihi Eder, MD, PhD

  University of Toronto
  Toronto, ON, Canada

  Disclosure information not submitted.

Please note: This session is not eligible for CME Credits through ACR.
This session will not be recorded for on-demand.

Psoriatic arthritis (PsA) is a complex immune-mediated disease with significant clinical burden, high rates of comorbid psoriasis, and a need for earlier, targeted intervention to prevent joint damage. TYK2 inhibition with the oral, highly selective agent deucravacitinib offers a novel approach with proven efficacy and favorable safety in PsA. Join leading experts to explore the science behind TYK2 targeting, review the latest clinical data, and enhance your strategies for personalized, evidence-based PsA care. 1.5 Category 1 AMA Physician's Recognition Award credits, American Academy of Physician Associates (AAPA) credits, and nursing continuing professional development (NCPD) contact hours. This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change. Developed and offered by PeerView Institute for Medical Education and supported by Bristol Myers Squibb. Not an official program of the ACR.